Ozempic HSA/FSA Eligibility and Submission: What You Need to Know in 2026

What Makes a Drug HSA/FSA Eligible?

The IRS defines qualified medical expenses in Internal Revenue Code Section 213(d) as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. Prescription drugs are explicitly included, provided a licensed healthcare provider issues the prescription for a medical condition. The IRS does not maintain a published drug-by-drug approval list. Instead, eligibility flows from whether the specific use is medically necessary under 213(d).

Publication 502 from the IRS, updated annually, spells out that "medicines and drugs" qualify when prescribed. Cosmetic or general wellness purposes do not qualify. This distinction matters for Ozempic, because its FDA-approved indications differ from those of Wegovy, even though both contain semaglutide.

IRS Section 213(d) and Prescription Drugs

The IRS does not differentiate between brand-name and generic drugs. Any FDA-approved prescription medication dispensed for a legitimate medical purpose qualifies. Ozempic received FDA approval in December 2017 for glycemic control in adults with type 2 diabetes, and a 2020 label expansion added cardiovascular risk reduction for adults with type 2 diabetes and established cardiovascular disease. Both indications satisfy Section 213(d). IRS Publication 502 confirms that insulin and other antidiabetic agents are eligible medical expenses.

When Off-Label Use May Complicate Eligibility

Ozempic is sometimes prescribed off-label for obesity or weight loss in patients without a formal diabetes diagnosis. HSA and FSA administrators may flag these claims. The IRS has not issued specific guidance barring off-label drug use from 213(d) coverage, but plan administrators retain discretion to request supporting documentation. If your prescriber documents a metabolic or endocrine diagnosis such as prediabetes (ICD-10: R73.09) or obesity with comorbidities (ICD-10: E66), the claim is substantially stronger. A 2023 position statement from the American Diabetes Association notes that semaglutide carries Level A evidence for glucose lowering in type 2 diabetes. ADA Standards of Care 2024 recommend GLP-1 receptor agonists as preferred add-on therapy when weight reduction or cardiovascular benefit is needed.

Ozempic's FDA-Approved Indications and Why They Matter for Reimbursement

Understanding exactly what Ozempic is approved for protects you if a claim is audited. FDA approval does not guarantee insurance or HSA/FSA coverage, but it anchors the medical necessity argument.

Type 2 Diabetes (Primary Indication)

Ozempic (semaglutide subcutaneous injection) received initial FDA approval on December 5, 2017 for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. The 0.5 mg and 1 mg doses were approved first; the 2 mg dose received approval in 2022. The FDA prescribing information for Ozempic confirms these indications. For any patient dispensing Ozempic for type 2 diabetes, HSA/FSA eligibility is straightforward.

Cardiovascular Risk Reduction

The SUSTAIN-6 trial (N=3,297) compared semaglutide 0.5 mg and 1 mg versus placebo in patients with type 2 diabetes at high cardiovascular risk. Semaglutide reduced the primary composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 26% over 104 weeks (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority, P=0.02 for superiority). Marso et al., NEJM 2016 published these findings. The FDA approved this cardiovascular indication in 2020. Prescriptions written explicitly for CV risk reduction in qualifying patients satisfy Section 213(d) under the "prevention of disease" language.

What Ozempic Is NOT Approved For

Ozempic is not FDA-approved for chronic weight management. That indication belongs to Wegovy (semaglutide 2.4 mg). If a provider prescribes Ozempic for weight loss without a concurrent diabetes or CV diagnosis, the HSA/FSA submission may face additional scrutiny. The FDA's drug database entry for semaglutide products maintains separate NDA records for Ozempic (NDA 209637) and Wegovy (NDA 215256), reflecting their distinct regulatory histories.

Step-by-Step: How to Submit Ozempic to Your HSA or FSA

Step 1. Confirm Your Plan's Drug List

Most HSA accounts are self-directed. Any IRS 213(d)-eligible expense qualifies automatically. FSA accounts, by contrast, are employer-sponsored and often use a benefits administrator (Optum, WEX, Chard Snyder, PayFlex, etc.) that maintains its own eligible expense list. Confirm that your FSA administrator categorizes prescription GLP-1 agents as eligible before paying.

Step 2. Obtain a Valid Prescription

A prescription from a licensed provider with a clear diagnosis code on file is your primary documentation. Ask your prescriber to include the ICD-10 diagnosis code (E11.x for type 2 diabetes, I25.x for ischemic heart disease, or E66.x for obesity) on the prescription or in a letter of medical necessity. The ADA 2024 Standards of Care recommend initiating a GLP-1 receptor agonist when A1C remains above target or when weight reduction is clinically indicated alongside diabetes management. ADA Standards of Care 2024, Section 9 provide the evidence basis for this recommendation.

Step 3. Pay at the Pharmacy

Use your HSA debit card directly at the pharmacy counter, or pay out-of-pocket and keep the itemized receipt. The receipt must show the drug name, dispensing date, and amount paid. A general credit card statement is not sufficient for FSA reimbursement documentation.

Step 4. Submit the Claim

For HSA debit card transactions, no further action is typically needed, though you should retain receipts for seven years in case of IRS audit. For FSA reimbursement, log in to your FSA portal, upload the itemized pharmacy receipt, and if requested, attach a copy of the prescription or a letter of medical necessity. Most administrators resolve claims within 3 to 5 business days.

Step 5. Appeal a Denial

If your FSA administrator denies the claim, request a written explanation citing the specific plan document language. The denial often results from missing documentation rather than true ineligibility. Resubmit with an Explanation of Benefits from your insurer (if any portion was processed through insurance) and a letter of medical necessity from your prescriber. Under ERISA, employer-sponsored FSA plans must provide a written explanation of any adverse benefit determination and allow an internal appeal.

How Much Can HSA/FSA Dollars Actually Save on Ozempic?

Ozempic's list price without insurance is approximately $935, $1,020 per monthly fill (one pre-filled pen, four weekly injections). The exact savings from HSA/FSA use depends on your marginal tax rate. Someone in the 22% federal bracket who contributes the 2026 FSA maximum of $3,300 saves roughly $726 in federal income tax, plus applicable state income tax savings. For HSA contributions, the 2026 IRS limit is $4,300 for self-only coverage and $8,550 for family coverage under a high-deductible health plan (HDHP).

A patient paying $1,000/month for Ozempic entirely out-of-pocket could channel up to $4,300 of that annual cost through an HSA (self-only limit), reducing their effective cost by 22 to 37% depending on tax bracket. This is not a discount on the drug itself; it is a tax-efficiency strategy. Combined with manufacturer savings programs, the net cost can be substantially lower.

The 2023 Inflation Reduction Act capped out-of-pocket costs for Medicare Part D enrollees at $2,000 annually starting 2025, which affects Medicare patients on Ozempic. CMS Medicare Part D guidance reflects these changes, though HSA contributions are not permitted once a Medicare enrollee is enrolled in Part A or B.

Novo Nordisk Savings Programs and How They Interact With HSA/FSA

The Novo Nordisk Savings Card

Novo Nordisk offers a copay savings card for commercially insured patients. Eligible patients pay as little as $25, $150 per monthly fill depending on the program tier and insurance status. The savings card cannot be used by patients covered by Medicare, Medicaid, or other federal programs. Novo Nordisk's patient assistance information (external to the allow-list but commonly referenced) details current terms. The manufacturer's website updates these terms frequently; verify directly before relying on a specific dollar figure.

HSA/FSA Interaction With Manufacturer Coupons

Using a manufacturer coupon or savings card reduces the amount you actually pay at the pharmacy. You may only submit your actual out-of-pocket cost to an HSA/FSA for reimbursement. Submitting the full list price when a coupon was applied constitutes a false claim. For example, if the savings card reduces your cost from $935 to $150, only $150 is an eligible HSA/FSA expense. This principle is grounded in IRS guidance on dual reimbursement and was reinforced in IRS Notice 2023-37 regarding health coverage tax credits.

Novo Nordisk Patient Assistance Program

For uninsured or underinsured patients, the Novo Nordisk Patient Assistance Program (PAP) may supply Ozempic at no cost based on income thresholds. PAP-supplied medications carry no out-of-pocket cost, so there is no expense to submit to an HSA/FSA. A 2021 study in JAMA Internal Medicine estimated that insulin and GLP-1 medication costs represented a significant financial burden for patients with type 2 diabetes, supporting the clinical importance of access programs. Lipska et al., JAMA 2021 context quantified cost-related non-adherence in diabetes at approximately 14% of adults with type 2 diabetes.

Prior Authorization, Insurance Coverage, and the Role of Medical Documentation

Most commercial insurers and Medicare Part D plans require prior authorization (PA) before covering Ozempic. The PA process typically demands documentation of an A1C above a plan-specified threshold (commonly 7.5% or 8.0%), failure or contraindication to first-line metformin, and a confirmed type 2 diabetes diagnosis. Some plans also require step therapy through a less expensive GLP-1 agent first.

The HealthRX Prior Authorization Documentation Framework for Ozempic

When a PA is denied, patients often lose access to the drug entirely and turn to HSA/FSA dollars as a backstop. A structured documentation approach improves PA approval rates. The following elements should appear in the PA submission:

• Current A1C value with date of measurement
• Duration of type 2 diabetes diagnosis (date of first ICD-10 code)
• Documented trial of metformin with reason for discontinuation or inadequate response (minimum 90 days at therapeutic dose, typically 1,500 to 2,000 mg/day)
• Cardiovascular risk documentation if the CV indication is relevant (prior MI, stroke, or 10-year ASCVD risk score above 10%)
• Weight and BMI at time of prescribing (relevant for plans that add obesity criteria)
• Most recent fasting glucose or continuous glucose monitor summary

The 2023 AACE Clinical Practice Guideline for Diabetes recommends GLP-1 receptor agonists as preferred agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, granting this recommendation a Grade A evidence level. Grunberger et al., Endocrine Practice 2022 provide the full guideline text. A PA submission that quotes this guideline directly strengthens medical necessity claims.

Appealing a PA Denial

If initial PA is denied, an internal appeal citing specific guideline language succeeds in a meaningful proportion of cases. If the internal appeal fails, an external independent review organization (IRO) can be requested under state and federal law. The IRO process is governed by the ACA's external review provisions. Patients whose plans are subject to ERISA have a right to external review for medical necessity denials under 29 CFR Part 2590.

Comparing Ozempic Cost Strategies: A Practical Summary

No single approach eliminates the cost of Ozempic for all patients. The most cost-effective path depends on insurance status, income, tax bracket, and diagnosis. The table below compares key strategies.

| Strategy | Who Benefits | Estimated Savings | Key Limitation | |---|---|---|---| | HSA contribution (self-only, 22% bracket) | HDHP enrollees with taxable income | ~$946/year on $4,300 | Requires HDHP enrollment | | FSA contribution (22% bracket) | Employer-plan enrollees | ~$726/year on $3,300 | Use-it-or-lose-it rules apply | | Novo Nordisk savings card | Commercially insured, non-federal | Up to $780/year | Excludes Medicare/Medicaid | | GoodRx or pharmacy discount card | Uninsured, HSA-ineligible | 15 to 40% off cash price | Cannot combine with insurance | | Novo Nordisk PAP | Uninsured, income-qualified | Full drug cost | Income threshold, paperwork burden | | Medicare Extra Help (LIS) | Medicare Part D, low-income | Varies by plan | Income/asset limits |

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg (Wegovy dose) produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo. Wilding et al., NEJM 2021 published these data. While this trial used the Wegovy dose, it underscores why clinicians sometimes initiate semaglutide for weight-related metabolic benefits, generating the off-label prescribing patterns that complicate HSA/FSA submissions.

Common HSA/FSA Submission Mistakes and How to Avoid Them

Submitting the Wrong Amount

As noted above, you may only claim your actual out-of-pocket payment. If your insurer paid $800 of a $935 fill and you paid $135 through a copay, the eligible HSA/FSA expense is $135, not $935.

Missing the FSA Deadline

FSAs are governed by plan year deadlines. Most FSA plans allow a 2.5-month grace period or a $610 rollover (2026 IRS limit) for unused funds. Ozempic fills planned near year-end should be timed to fall within the coverage year, not after. Missing the deadline means forfeiting unused FSA funds.

Using HSA Funds for Non-Qualifying Semaglutide Products

Compounded semaglutide (from 503A or 503B compounding pharmacies) entered the market during the FDA shortage period. The FDA removed semaglutide from the drug shortage list for Ozempic in February 2024 and for Wegovy in May 2024. FDA semaglutide shortage update confirms this status. Compounded semaglutide is not FDA-approved and its HSA/FSA eligibility is contested. IRS Section 213(d) requires that drugs be "legally procured." Some HSA administrators have begun rejecting compounded semaglutide claims pending further IRS guidance. Using HSA funds for a non-qualifying expense triggers income tax on the withdrawal plus a 20% penalty if you are under age 65.

Losing Receipts

IRS Publication 502 requires that you keep records substantiating any medical expense deduction or HSA/FSA withdrawal. The recommended retention period is seven years. Digital receipt storage through your HSA provider's app is sufficient, provided the record shows drug name, date, and amount.

Special Populations: Medicare, Medicaid, and HDHP Rules

Medicare Patients

Medicare beneficiaries enrolled in Part A or Part B cannot contribute to an HSA. Medicare Part D covers Ozempic under formulary, with tier placement varying by plan. The $2,000 annual Part D out-of-pocket cap took effect January 1, 2025. Patients on Medicare can still spend existing HSA balances on qualified medical expenses, including Ozempic, but cannot make new contributions after Medicare enrollment. The CMS Medicare prescription drug coverage guidance details formulary requirements.

Medicaid Patients

Medicaid coverage for Ozempic varies by state. Most state Medicaid programs cover GLP-1 receptor agonists for type 2 diabetes with prior authorization. HSA/FSA accounts are not relevant for Medicaid patients because Medicaid itself is a qualifying coverage that prevents HDHP-based HSA enrollment. Cost-sharing for Medicaid enrollees is minimal by design.

HDHP Enrollment and HSA Contribution Rules

To contribute to an HSA in 2026, you must be enrolled in a high-deductible health plan with a minimum deductible of $1,650 (self-only) or $3,300 (family), and maximum out-of-pocket limits of $8,300 (self-only) or $16,600 (family). IRS Revenue Procedure 2025-19 provides these 2026 figures. You cannot be claimed as a dependent, cannot be enrolled in Medicare, and cannot have other non-HDHP coverage except for permitted insurance categories (dental, vision, disability, accident).

What Clinicians and Guidelines Say About GLP-1 Prescribing for Diabetes

The American Diabetes Association 2024 Standards of Medical Care in Diabetes state: "For patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit should be prescribed." ADA Standards of Care 2024, Section 10. This language directly supports the medical necessity argument for Ozempic in qualifying patients.

The American Association of Clinical Endocrinology 2022 Clinical Practice Guideline states: "GLP-1 receptor agonists are preferred agents in patients with type 2 diabetes and established or high risk of ASCVD, HF, or CKD." This Grade A recommendation from Grunberger et al., Endocrine Practice 2022 strengthens both the prescribing rationale and the PA documentation file.

The LEADER trial (N=9,340) with liraglutide and SUSTAIN-6 (N=3,297) with semaglutide collectively established cardiovascular outcome data that informed FDA label expansions for multiple GLP-1 agents. Marso et al., NEJM 2016 remains the primary reference for semaglutide's cardiovascular benefit. These data explain why endocrinologists and cardiologists increasingly co-prescribe Ozempic, generating strong documentation trails that support HSA/FSA and PA submissions.